4/21
02:04 am
meip
MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Medium
Report
MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
4/13
02:04 am
meip
MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Low
Report
MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
4/12
12:11 pm
meip
MEI Pharma, Inc. (NASDAQ: MEIP) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $7.00 price target on the stock.
Medium
Report
MEI Pharma, Inc. (NASDAQ: MEIP) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $7.00 price target on the stock.
4/11
02:19 pm
meip
MEI Pharma shelves plans for a second return of capital [Seeking Alpha]
Low
Report
MEI Pharma shelves plans for a second return of capital [Seeking Alpha]
4/11
08:14 am
meip
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients [Yahoo! Finance]
Medium
Report
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients [Yahoo! Finance]
4/11
08:14 am
meip
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 [Yahoo! Finance]
Medium
Report
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 [Yahoo! Finance]
4/11
08:02 am
meip
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
Medium
Report
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
4/11
08:00 am
meip
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
Medium
Report
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
4/10
08:00 am
meip
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Medium
Report
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
3/26
08:25 am
meip
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia [Yahoo! Finance]
Medium
Report
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia [Yahoo! Finance]
3/26
08:00 am
meip
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Low
Report
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
2/28
11:06 pm
meip
MEI Pharma, Inc. (NASDAQ: MEIP) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
MEI Pharma, Inc. (NASDAQ: MEIP) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
2/15
01:06 pm
meip
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
Low
Report
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
2/14
09:11 am
meip
MEI Pharma, Inc. (NASDAQ: MEIP) had its price target lowered by analysts at Stifel Nicolaus from $8.00 to $7.00. They now have a "hold" rating on the stock.
Low
Report
MEI Pharma, Inc. (NASDAQ: MEIP) had its price target lowered by analysts at Stifel Nicolaus from $8.00 to $7.00. They now have a "hold" rating on the stock.
2/13
07:25 pm
meip
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates [Yahoo! Finance]
Low
Report
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates [Yahoo! Finance]
2/13
05:12 pm
meip
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights [Yahoo! Finance]
Medium
Report
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights [Yahoo! Finance]
2/13
05:05 pm
meip
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
Medium
Report
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
2/13
01:22 am
meip
MEI Pharma, Inc. (NASDAQ: MEIP) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
MEI Pharma, Inc. (NASDAQ: MEIP) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
2/11
09:51 am
meip
GreenWood Investors Year End 2023 Letter [Seeking Alpha]
Low
Report
GreenWood Investors Year End 2023 Letter [Seeking Alpha]
2/8
06:59 am
meip
Is MEI Pharma (MEIP) Attractively Priced? [Yahoo! Finance]
Medium
Report
Is MEI Pharma (MEIP) Attractively Priced? [Yahoo! Finance]
2/5
01:07 am
meip
MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Medium
Report
MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
2/2
06:14 pm
meip
MEI Pharma, Inc. (NASDAQ: MEIP) was downgraded by analysts at TheStreet from a "c-" rating to a "d+" rating.
Medium
Report
MEI Pharma, Inc. (NASDAQ: MEIP) was downgraded by analysts at TheStreet from a "c-" rating to a "d+" rating.
1/28
01:34 am
meip
MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.